InvestorsObserver
Sign Up Login

KZIA Kazia Therapeutics Ltd

$10.14 $-0.02 (-0.20%)
Add to Watchlist Compare
Overall

KZIA Stock Analysis Overview

What this means: Kazia Therapeutics Ltd (KZIA) gets an Overall Rank of 67, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. KZIA's 67 means that it ranks higher than 67% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

KZIA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

KZIA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

KZIA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

KZIA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

KZIA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

KZIA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

KZIA Stock Analysis Overview

What this means: Kazia Therapeutics Ltd (KZIA) gets an Overall Rank of 67, which is an above average rank under InvestorsObserver's stock ranking system. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a percentile-ranked value. KZIA's 67 means that it ranks higher than 67% of stocks.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full AMZN report

KZIA Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

KZIA Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

KZIA Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

KZIA Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

KZIA Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

KZIA Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Kazia Therapeutics Ltd (KZIA) Analyst Forecast

  • Last Price $10.14
  • Previous Close $10.16
  • Change $-0.02
  • Open $10.20
  • Volume 96,928
  • Avg. Volume (100-day) 348,747
  • Market Cap 95,948,087
  • Days Range 9.63 - 10.226
  • 52-week Range 2.47 - 15.85
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date —
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 0.397
  • PEG Ratio —
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing innovative anti-cancer drugs. The group is developing GDC-0084, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others.
View Interactive KZIA chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Dare Bioscience Inc (DARE) (DARE) $3.00
Novan Inc (NOVN) (NOVN) $1.31
Cocrystal Pharma Inc (COCP) (COCP) $2.35
Palatin Technologies (PTN) (PTN) $1.01
Lineage Cell Therapeutics Inc (LCTX) (LCTX) $3.00
Mereo Biopharma Group Plc ADR (MREO) (MREO) $3.27
Tenax Therapeutics (TENX) (TENX) $2.43
Vascular Biogen. Ord (VBLT) (VBLT) $2.50
Vistagen Therap. Com (VTGN) (VTGN) $2.28
Diamedica Therapeutics Inc (DMAC) (DMAC) $9.40